Home > News > pharmaceutical-news

Venus Remedies Gets Market Authorisation For Meropenem

Mumbai, Nov 15 : Mid-Sized Drugmaker Venus Remedies Ltd has said it had obtained approval for Market Authorization (MA) from the Modern Humanities Research Association (MHRA), UK, via DCP route, covering Ireland, Poland, Slovenia, Netherlands, Finland, Austria, Slovakia, Denmark, Germany, Sweden, France and Italy, for its generic broad spectrum injectable antibiotic carbapenem.

The company said it was all set to launch Meropenem soon within this fiscal year.

Besides this, it also got Market Authorization for the same product from New Zealand's Ministry of Health, a release said.

MA grants from both the territories has opened doors for Venus to enter into the highly lucrative penems market of USD 250 million in Europe and USD20 million in New Zealand.

Meropenem is a broad spectrum anti-bacterial agent of carbapenem family, indicated as empirical therapy prior to the identification of causative organisms, or for disease caused by single or multiple susceptible bacteria in both adults and children with a broad range of serious infections.

At present, Meropenem sales account for USD906 million across the globe, which is estimated to grow to USD1,006 million by 2012.

Presently, Venus is already selling Meropenem in various market sand is in the process of extending its footprints and sales operations in the most regulated markets also, which include countries like Netherlands, France, Italy, Germany and few more. (UNI -Posted on / )